CD274 and non-small cell lung carcinoma: A case study report of a NSCLC patient treated with Durvalumab as a maintenance therapy after chemotherapy and radiotherapy showed a 3-fold drop in the level of IL-4Rα+ M-MDSC and in the expression of the CD274 (PD-L1), PTGS2, IL10, and IDO1 genes in PBMCs after two administrations of the anti-PD-L1 antibody, accompanied by a reduction in the suppressive potential of these cells compared to baseline.